World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
42154
World Ranking
10312
National Ranking
23

John Crown publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John Crown sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 640 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John Crown D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John Crown sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

John Crown is affiliated with Dublin City University in Ireland and has contributed extensively to the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research output demonstrates a strong focus on oncology and related biomedical sciences.

The main fields of study covered by Crown include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader fields, Crown's work is concentrated in several subfields, particularly:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging

The research topics that feature prominently in Crown's publications are:

  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Immunotherapy and Biomarkers
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Monoclonal and Polyclonal Antibodies Research

John Crown has collaborated frequently with several co-authors, notably:

  • Denis M. Collins
  • Alex J. Eustace
  • Bryan T. Hennessy
  • Janice M. Walshe
  • Neil T. Conlon

Their published work appears regularly in a range of scientific venues, with the most frequent being:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Breast Cancer Research and Treatment
  • Investigational New Drugs

Several recent papers provide insight into Crown's research emphasis and collaborations. Notable papers include:

  • "Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial" (2020), published in The Lancet
  • "Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial" (2020), Journal of Clinical Oncology
  • "MYC as a target for cancer treatment" (2021), Cancer Treatment Reviews
  • "Targeting p53 for the treatment of cancer" (2020), Seminars in Cancer Biology
  • "Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials" (2021), The Lancet Oncology

Best Publications

  • Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

    Charles E. Geyer;John Forster;Deborah Lindquist;Stephen Chan

  • Adjuvant trastuzumab in HER2-positive breast cancer.

    Dennis Slamon;Wolfgang Eiermann;Nicholas Robert;Tadeusz Pienkowski

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Gunter Von Minckwitz;Chiun Sheng Huang;Max S. Mano;Sibylle Loibl

  • The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

    Richard S Finn;John P Crown;Istvan Lang;Katalin Boer

  • Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

    Sherene Loi;Nicolas Sirtaine;Fanny Piette;Roberto Salgado

  • A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

    David Cameron;Michelle Casey;Michael Press;Deborah Lindquist

  • Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

    D. Slamon;W. Eiermann;N. Robert;T. Pienkowski

  • Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

    Stephen Chan;Kay Friedrichs;Daniel Noel;Tamàs Pintér

  • Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis

    Colin Clarke;Stephen F. Madden;Padraig Doolan;Sinead T. Aherne

  • The taxanes: an update

    John Crown;Michael O'Leary

  • Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.

    Claire Corcoran;Sweta Rani;Keith O’Brien;Amanda O’Neill

  • Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >= 2 HER2-Directed Regimens: Phase III NALA Trial

    Cristina Saura;Mafalda Oliveira;Yin-Hsun Feng;Ming-Shen Dai

  • Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

    B. Corkery;J. Crown;M. Clynes;N. O'Donovan

  • Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.

    Neil A. O'Brien;Brigid C. Browne;Lucy Chow;Yuhua Wang

  • Mutant p53 as a target for cancer treatment.

    Michael J. Duffy;Naoise C. Synnott;John Crown

  • Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

    Mark D. Pegram;Tadeusz Pienkowski;Donald W. Northfelt;Wolfgang Eiermann

  • NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

    Louis Fehrenbacher;Reena S. Cecchini;Charles E. Geyer;Priya Rastogi

  • Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

    Vicente Valero;John Forbes;Mark D. Pegram;Tadeusz Pienkowski

  • Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience

    John Crown;Michael O’Leary;Wei-Seong Ooi

  • Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.

    A D Seidman;B S Reichman;J P Crown;T J Yao

Frequent Co-Authors

Michael J. Duffy
Michael J. Duffy University College Dublin
Martin Clynes
Martin Clynes Dublin City University
Bryan T. Hennessy
Bryan T. Hennessy Beaumont Hospital
Larry Norton
Larry Norton Memorial Sloan Kettering Cancer Center
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
John R. Mackey
John R. Mackey University of Alberta
Marc Buyse
Marc Buyse Hasselt University
Angelo Di Leo
Angelo Di Leo Academy for Urban School Leadership
Michael F. Press
Michael F. Press University of Southern California

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering studying medicine in the USA, there are several related online degree options and career pathways to explore. Many students choose to start with specialized healthcare fields that offer flexible and affordable online programs.

Health information management is a rapidly growing area, and enrolling in rhit programs online can prepare you for roles that manage crucial medical data. Another increasingly popular choice is completing medical billing and coding online, which opens up administrative positions in hospitals, clinics, and insurance companies.

For those aiming for clinical work, nurse practitioner programs provide advanced training to deliver patient care at a higher level. If you're looking for a more accessible entry point, there are many cheapest online nursing programs that lead to RN licensure or other nursing roles while allowing you to study at your own pace.

These online healthcare programs can serve as a stepping stone towards a future medical degree or help jumpstart a rewarding healthcare career.

Best Scientists Citing John Crown

Trending Scientists

Recently Published Articles